Cristiano Ruch Werneck Guimarães
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Cristiano Ruch Werneck Guimarães has a total of 299 co-authors. Here are the top co-authors by number of shared publications:
Alessandra Mascarello
Aché Laboratórios Farmacêuticos S.A.
8 shared publications- Hatylas Azevedo
Aché Laboratórios Farmacêuticos S.A., Guarulhos, São Paulo, 07034-904, Brazil
7 shared publications Ricardo Bicca de Alencastro
Physical Organic Chemistry Group, Departamento de Química Organica, Instituto de Química, Universidade Federal do Rio de Janeiro, Cidade Universitária, CT, Bloco A, lab. 609, Rio de Janeiro, RJ 21949-900, Brazil, and Department of Chemistry, Yale University, 225 Prospect St., New Haven, Connecticut 06520-8107
7 shared publicationsWilliam L. Jorgensen
Department of Chemistry, Yale University, New Haven, Connecticut 06520, United States
7 shared publicationsCésar Augusto Fernandes de Oliveira
Physical Organic Chemistry Group, Departamento de Química Organica, Instituto de Química, Universidade Federal do Rio de Janeiro, Cidade Universitária, CT, Bloco A, lab. 609, Rio de Janeiro, RJ 21949-900, Brazil, and Department of Chemistry, Yale University, 225 Prospect St., New Haven, Connecticut 06520-8107
6 shared publicationsGabriela Barreiro
Department of Chemistry, Yale University, 225 Prospect Street, New Haven, CT 06520-8107, USA
6 shared publications
Latest Publications
- 12 December 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (24) , 26121-26174
Design, Optimization, and Biological Evaluation of First-in-Class Triple Inhibitors of SGLT1, SGLT2, and DPP4 for Type 2 Diabetes Mellitus
Type 2 diabetes care has evolved with DPP4, SGLT2, and SGLT1/2 inhibitors, but still many patients face hyperglycemia and high cardiorenal risk. Here, we designed unprecedented triple-targeted inhibitors of SGLT1/2 and DPP4 by leveraging information on binding modes of existing inhibitors. Balanced inhibition was achieved across targets while maintaining desirable pharmacokinetics with long-lasting kidney exposure. Lead compounds 64 (IC50: DPP4 = 356 nM, SGLT1 = 1.29 μM, SGLT2 = 170 nM), 99 (58 nM, 23 nM, 0.8 nM), and 101 (72 nM, 6.7 nM, 0.8 nM) induced glucosuria in nondiabetic rats. Following oral glucose challenge in Zucker diabetic rats, they demonstrated statistically superior plasma glycemic control versus SGLT2-selective inhibitor dapagliflozin and conferred a prolonged increase in active GLP-1 relative to the SGLT1/2 inhibitor sotagliflozin, implying synergistic SGLT1 and DPP4 inhibition. These results support triple-targeted inhibitors as multitarget, multiorgan drug candidates for improved glycemic control and cardiorenal benefits.
- 12 December 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (24) , 26121-26174
Design, Optimization, and Biological Evaluation of First-in-Class Triple Inhibitors of SGLT1, SGLT2, and DPP4 for Type 2 Diabetes Mellitus
Type 2 diabetes care has evolved with DPP4, SGLT2, and SGLT1/2 inhibitors, but still many patients face hyperglycemia and high cardiorenal risk. Here, we designed unprecedented triple-targeted inhibitors of SGLT1/2 and DPP4 by leveraging information on binding modes of existing inhibitors. Balanced inhibition was achieved across targets while maintaining desirable pharmacokinetics with long-lasting kidney exposure. Lead compounds 64 (IC50: DPP4 = 356 nM, SGLT1 = 1.29 μM, SGLT2 = 170 nM), 99 (58 nM, 23 nM, 0.8 nM), and 101 (72 nM, 6.7 nM, 0.8 nM) induced glucosuria in nondiabetic rats. Following oral glucose challenge in Zucker diabetic rats, they demonstrated statistically superior plasma glycemic control versus SGLT2-selective inhibitor dapagliflozin and conferred a prolonged increase in active GLP-1 relative to the SGLT1/2 inhibitor sotagliflozin, implying synergistic SGLT1 and DPP4 inhibition. These results support triple-targeted inhibitors as multitarget, multiorgan drug candidates for improved glycemic control and cardiorenal benefits.
- 24 September 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (19) , 16928-16929
Career Transitions That Require a Lot of Energy and Take You to Excited States Will Eventually Result in Brighter Professional Achievements
- 24 September 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (19) , 16928-16929
Career Transitions That Require a Lot of Energy and Take You to Excited States Will Eventually Result in Brighter Professional Achievements
- Open Access
- 19 July 2023
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 22 (12) , 3445-3458
Nonclinical evaluation of a Vitis vinifera extract towards a novel antiaging cosmetic ingredient
Background: Skin aging is regulated by multiple physiological processes, such as oxidative stress. Natural products have been considered as a promising source of antioxidant compounds. As a result, few innovative products on the market based on natural products tackle additional underlying mechanisms of skin aging.Aims: The present work reports the nonclinical evaluation of a novel extract from the skin of V. vinifera fruits (codified as ACH37 extract), with the aim of supporting its use as an antiaging cosmetic ingredient candidate in clinical trials.Methods: We employed enzymatic, phenotypic, and gene expression assays, both in vitro and ex vivo, to investigate the action of the ACH37 extract in different biological processes that could be related to skin aging mechanisms.Results: The ACH37 extract was able to scavenge reactive oxygen species (DPPH, O2−), prevent inflammation (LPS‐ and UV‐induced COX‐2, IL‐1β, and IL‐8 expression), modulate extracellular matrix remodeling (inhibiting elastase, MMP‐1, MMP‐3, and MMP‐12, as well as associated expression), increase telomere length, telomerase activity, and reverse the UV‐induced suppression of genes involved in skin protection. In addition, the ACH37 extract permeated human skin explants and presented antioxidant efficacy ex vivo.Conclusion: The results indicated that the ACH37 extract acts on multiple targets commonly related to skin aging, being a promising antiaging active ingredient candidate to be further investigated in clinical trials.
- 19 July 2023
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 22 (12) , 3445-3458
Open AccessNonclinical evaluation of a Vitis vinifera extract towards a novel antiaging cosmetic ingredient
Background: Skin aging is regulated by multiple physiological processes, such as oxidative stress. Natural products have been considered as a promising source of antioxidant compounds. As a result, few innovative products on the market based on natural products tackle additional underlying mechanisms of skin aging.Aims: The present work reports the nonclinical evaluation of a novel extract from the skin of V. vinifera fruits (codified as ACH37 extract), with the aim of supporting its use as an antiaging cosmetic ingredient candidate in clinical trials.Methods: We employed enzymatic, phenotypic, and gene expression assays, both in vitro and ex vivo, to investigate the action of the ACH37 extract in different biological processes that could be related to skin aging mechanisms.Results: The ACH37 extract was able to scavenge reactive oxygen species (DPPH, O2−), prevent inflammation (LPS‐ and UV‐induced COX‐2, IL‐1β, and IL‐8 expression), modulate extracellular matrix remodeling (inhibiting elastase, MMP‐1, MMP‐3, and MMP‐12, as well as associated expression), increase telomere length, telomerase activity, and reverse the UV‐induced suppression of genes involved in skin protection. In addition, the ACH37 extract permeated human skin explants and presented antioxidant efficacy ex vivo.Conclusion: The results indicated that the ACH37 extract acts on multiple targets commonly related to skin aging, being a promising antiaging active ingredient candidate to be further investigated in clinical trials.
- Open Access
- 1 November 2020
- Published by Elsevier in Neurobiology of Stress
- Vol. 13, 100226
Brain-wide mapping of c-fos expression in the single prolonged stress model and the effects of pretreatment with ACH-000029 or prazosin
- 1 November 2020
- Published by Elsevier in Neurobiology of Stress
- Vol. 13, 100226
Open AccessBrain-wide mapping of c-fos expression in the single prolonged stress model and the effects of pretreatment with ACH-000029 or prazosin
- Open Access
- 1 March 2020
- Published by Elsevier in Neuropharmacology
- Vol. 164, 107912
The serotonergic and alpha-1 adrenergic receptor modulator ACH-000029 ameliorates anxiety-like behavior in a post-traumatic stress disorder model
- 1 March 2020
- Published by Elsevier in Neuropharmacology
- Vol. 164, 107912
Open AccessThe serotonergic and alpha-1 adrenergic receptor modulator ACH-000029 ameliorates anxiety-like behavior in a post-traumatic stress disorder model
- Open Access
- 1 December 2019
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 95, 109707
Preclinical characterization of ACH-000029, a novel anxiolytic compound acting on serotonergic and alpha-adrenergic receptors
- 1 December 2019
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 95, 109707
Open AccessPreclinical characterization of ACH-000029, a novel anxiolytic compound acting on serotonergic and alpha-adrenergic receptors
- Open Access
- 19 August 2019
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 10 (9) , 1266-1271
Development of Pyridine-based Inhibitors for the Human Vaccinia-related Kinases 1 and 2
Vaccinia-related kinases 1 and 2 (VRK1 and VRK2) are human Ser/Thr protein kinases associated with increased cell division and neurological disorders. Nevertheless, the cellular functions of these proteins are not fully understood. Despite their therapeutic potential, there are no potent and specific inhibitors available for VRK1 or VRK2. We report here the discovery and elaboration of an aminopyridine scaffold as a basis for VRK1 and VRK2 inhibitors. The most potent compound for VRK1 (26) displayed an IC50 value of 150 nM and was fairly selective in a panel of 48 human kinases (selectivity score S(50%) of 0.04). Differences in compound binding mode and substituent preferences between the two VRKs were identified by the structure−activity relationship combined with the crystallographic analysis of key compounds. We expect our results to serve as a starting point for the design of more specific and potent inhibitors against each of the two VRKs.
- 19 August 2019
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 10 (9) , 1266-1271
Open AccessDevelopment of Pyridine-based Inhibitors for the Human Vaccinia-related Kinases 1 and 2
Vaccinia-related kinases 1 and 2 (VRK1 and VRK2) are human Ser/Thr protein kinases associated with increased cell division and neurological disorders. Nevertheless, the cellular functions of these proteins are not fully understood. Despite their therapeutic potential, there are no potent and specific inhibitors available for VRK1 or VRK2. We report here the discovery and elaboration of an aminopyridine scaffold as a basis for VRK1 and VRK2 inhibitors. The most potent compound for VRK1 (26) displayed an IC50 value of 150 nM and was fairly selective in a panel of 48 human kinases (selectivity score S(50%) of 0.04). Differences in compound binding mode and substituent preferences between the two VRKs were identified by the structure−activity relationship combined with the crystallographic analysis of key compounds. We expect our results to serve as a starting point for the design of more specific and potent inhibitors against each of the two VRKs.
- Open Access
- 4 March 2019
- Published by American Chemical Society (ACS) in ChemRxiv
Development of Pyridine-Based Inhibitors for the Human Vaccinia-Related Kinases 1 and 2
Vaccinia-related kinases 1 and 2 (VRK1 and VRK2) are human Ser/Thr protein kinases associated with increased cell division and neurological disorders. Nevertheless, the cellular functions of these proteins are not fully understood. Despite their therapeutic potential, there are no inhibitors available for VRK1 or VRK2. We report here the discovery and elaboration of an aminopyridine scaffold as a basis for VRK1 and VRK2 inhibitors. The most potent compounds displayed KD values of 190 nM and 401 nM for VRK1 and VRK2, respectively. Differences in compound binding mode and substituent preferences between the two VRKs were identified by the series structure-activity relationship combined with the crystallographic analysis of key compounds. We expect that our results will serve as a starting point for the design of specific and potent inhibitors against each of the two VRKs based on a pyridine scaffold.
- 4 March 2019
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessDevelopment of Pyridine-Based Inhibitors for the Human Vaccinia-Related Kinases 1 and 2
Vaccinia-related kinases 1 and 2 (VRK1 and VRK2) are human Ser/Thr protein kinases associated with increased cell division and neurological disorders. Nevertheless, the cellular functions of these proteins are not fully understood. Despite their therapeutic potential, there are no inhibitors available for VRK1 or VRK2. We report here the discovery and elaboration of an aminopyridine scaffold as a basis for VRK1 and VRK2 inhibitors. The most potent compounds displayed KD values of 190 nM and 401 nM for VRK1 and VRK2, respectively. Differences in compound binding mode and substituent preferences between the two VRKs were identified by the series structure-activity relationship combined with the crystallographic analysis of key compounds. We expect that our results will serve as a starting point for the design of specific and potent inhibitors against each of the two VRKs based on a pyridine scaffold.
- Open Access
- 1 January 2019
- Published by Sociedade Brasileira de Quimica (SBQ) in Journal of the Brazilian Chemical Society
- Vol. 30 (7) , 1415-1424
Characterization and in silico Mutagenic Assessment of a New Betahistine Degradation Impurity
- 1 January 2019
- Published by Sociedade Brasileira de Quimica (SBQ) in Journal of the Brazilian Chemical Society
- Vol. 30 (7) , 1415-1424
Open AccessCharacterization and in silico Mutagenic Assessment of a New Betahistine Degradation Impurity
- Open Access
- 30 March 2018
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 22 (4) , 467-488
Synthetic Strategies toward SGLT2 Inhibitors
Gliflozins are an important class of prescription drugs used to treat type II diabetes. They reduce blood sugar levels by targeting the sodium-glucose transport protein 2 (SGLT2) and consequently inhibit glucose reabsorption in the kidney. There are currently several FDA-approved gliflozins as well as others in the pipeline to be launched in the next few years. This review describes the synthetic strategies used for manufacturing SGLT2 inhibitors on both bench and industrial scales. Moreover, the drawbacks to the strategies and the improvements made to obtain selected gliflozins and their glucose derivatives over the years are highlighted.
- 30 March 2018
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 22 (4) , 467-488
Open AccessSynthetic Strategies toward SGLT2 Inhibitors
Gliflozins are an important class of prescription drugs used to treat type II diabetes. They reduce blood sugar levels by targeting the sodium-glucose transport protein 2 (SGLT2) and consequently inhibit glucose reabsorption in the kidney. There are currently several FDA-approved gliflozins as well as others in the pipeline to be launched in the next few years. This review describes the synthetic strategies used for manufacturing SGLT2 inhibitors on both bench and industrial scales. Moreover, the drawbacks to the strategies and the improvements made to obtain selected gliflozins and their glucose derivatives over the years are highlighted.